methylene blue had some formulation issues and thay have re-engineered a new product. It is in phase 1, but have heeard that they are trying to get a partner and go straight to ph 3.
Bapinuzumab showed a 25% reduction in total tau and phosphotau in ph 2 that was very near statisitical significancee with a small sample size. i think this is promising and one of the reasons I came to believe more in this program.
News 
Market Data 
Discover 
